LEADER 02580nam 2200601 450 001 9910460617803321 005 20200520144314.0 010 $a0-309-31001-6 035 $a(CKB)3710000000336166 035 $a(EBL)3379407 035 $a(SSID)ssj0001467018 035 $a(PQKBManifestationID)11892276 035 $a(PQKBTitleCode)TC0001467018 035 $a(PQKBWorkID)11504063 035 $a(PQKB)11321513 035 $a(MiAaPQ)EBC3379407 035 $a(Au-PeEL)EBL3379407 035 $a(CaPaEBR)ebr11003355 035 $a(OCoLC)904080937 035 $a(EXLCZ)993710000000336166 100 $a20150121h20142014 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aCharacterizing and communicating uncertainty in the assessment of benefits and risks of pharmaceutical products $eworkshop summary /$fDenise Caruso, Rebecca A. English, Anne B. Claiborne 210 1$aWashington, District of Columbia :$cThe National Academies Press,$d2014. 210 4$dİ2014 215 $a1 online resource (150 p.) 300 $aDescription based upon print version of record. 311 $a0-309-31000-8 320 $aIncludes bibliographical references. 327 $a""Front Matter""; ""Reviewers""; ""Contents""; ""Boxes, Figures, and Table""; ""Acronyms""; ""1 Introduction""; ""2 Identifying and Characterizing Uncertainty""; ""3 The Regulators Challenge""; ""4 Basic Methodologies and Applications for Understanding and Evaluating Uncertainty""; ""5 Communicating Uncertainty""; ""6 Final Reflections on Ways to Characterize and Communicate Uncertainty""; ""References""; ""Appendix A: Workshop Agenda""; ""Appendix B: FDA Case Studies""; ""Appendix C: Bibliography""; ""Appendix D: Participant Biographies"" 606 $aRisk assessment$vCongresses 606 $aCommunication$vCongresses 608 $aElectronic books. 615 0$aRisk assessment 615 0$aCommunication 676 $a363.1 700 $aCaruso$b Denise$0928102 702 $aEnglish$b Rebecca A. 702 $aClaiborne$b Anne B. 712 02$aBoard on Health Sciences Policy. 712 02$aInstitute of Medicine (U.S.).$bForum on Drug Discovery, Development, and Translation. 712 02$aInstitute of Medicine (U.S.) 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910460617803321 996 $aCharacterizing and communicating uncertainty in the assessment of benefits and risks of pharmaceutical products$92085694 997 $aUNINA LEADER 03728nam 2200697 a 450 001 9910956416503321 005 20240314004729.0 010 $a0-7391-7821-0 010 $a0-7391-7822-9 035 $a(CKB)2550000001096172 035 $a(EBL)1246191 035 $a(OCoLC)852159087 035 $a(SSID)ssj0000915565 035 $a(PQKBManifestationID)12412464 035 $a(PQKBTitleCode)TC0000915565 035 $a(PQKBWorkID)10868720 035 $a(PQKB)11163533 035 $a(Au-PeEL)EBL1246191 035 $a(CaPaEBR)ebr10728083 035 $a(CaONFJC)MIL502750 035 $a(MiAaPQ)EBC1246191 035 $a(EXLCZ)992550000001096172 100 $a20130708d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aDesigner biology $ethe ethics of intensively engineering biological and ecological systems /$fedited by John Basl and Ronald L. Sandler 205 $a1st ed. 210 $aLanham, Md. $cLexington Books$dc2013 215 $a1 online resource (304 p.) 300 $aDescription based upon print version of record. 311 08$a0-7391-8487-3 311 08$a1-299-71499-4 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aContents; Acknowledgments; Introduction; I: Engineering Humans; Chapter One: Sex Selection and the Value-Ladenness of the Procreative Liberty Framework; Chapter Two: The Ethics of Embryo Selection; Chapter Three: Assessing Efficacy of "Neuroenhancing" Drugs; Chapter Four: Engineering for Virtue? Toward Holistic Moral Enhancement; Chapter Five: Radical Human Enhancement, and What's Wrong with It; Chapter Six: Human Engineering and Climate Change; II: Engineering the Environment; Chapter Seven: The Human Influence; Chapter Eight: Why Scientists Should Get Out of Nature Conservation 327 $aChapter Nine: What It Takes to Justify Geoengineering the ClimateChapter Ten: Remediation vs. Steering; III: Engineering Life; Chapter Eleven: Sensitivity Enhancement; Chapter Twelve: The Capacities, Interests, and Organization of Artifactual Organisms; Chapter Thirteen: How to Evolve a Good of Your Own; Conclusion; Index; About the Contributors 330 $aDesigner Biology: The Ethics of Intensively Engineering Biological and Ecological Systems consists of thirteen chapters (twelve of them original to the collection) that address the ethical issues raised by technological intervention and design across a broad range of biological and ecological systems. Among the technologies addressed are geoengineering, human enhancement, sex selection, genetic modification, and synthetic biology. 606 $aBioethics 606 $aBioengineering$xMoral and ethical aspects 606 $aGenetic engineering$xMoral and ethical aspects 606 $aEnvironmental engineering$xMoral and ethical aspects 606 $aBiotic communities$xEffect of human beings on$xMoral and ethical aspects 606 $aGeotechnical engineering$xMoral and ethical aspects 615 0$aBioethics. 615 0$aBioengineering$xMoral and ethical aspects. 615 0$aGenetic engineering$xMoral and ethical aspects. 615 0$aEnvironmental engineering$xMoral and ethical aspects. 615 0$aBiotic communities$xEffect of human beings on$xMoral and ethical aspects. 615 0$aGeotechnical engineering$xMoral and ethical aspects. 676 $a174.957 701 $aBasl$b John$01846982 701 $aSandler$b Ronald L$0888279 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910956416503321 996 $aDesigner biology$94431969 997 $aUNINA